|Avivagen Inc -- Canada Stock|| |
CAD 0.93 0.01 1.06%
Mr. Chris Boland was appointed as Chief Financial Officer of Avivagen Inc., with effect from July 12, 2012
CFO Since 2012
Boland is a Canadian chartered accountant and also holds the certified management accountant designation. Prior to his present appointment, Mr. Boland was in public practice . Earlier positions at other organizations include general manager at Canada Post Corporationrationrationration, chief financial officer and vicepresident finance at Optiwave Corporationrationrationration, director of tax and treasury, controller, at Eftia OSS, manager of financial reporting and controller at the Canadian Bank Note, and manager of financial reporting at Mitel Corporationrationrationration. He was also an auditor at the Office of the Auditor General and manager at Treasury Board.
The company has return on total asset (ROA)
of (83.76) %
which means that it has lost $83.76 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (9.0) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 4.34 M in total debt. Avivagen Inc has Current Ratio of 5.47 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Avivagen, Inc. develops and commercializes various solutions to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal?s own health defenses. Avivagen Inc (VIV) is traded on TSX Venture Exchange in Canada. It is located in Ottawa, ON KA R and employs 19 people.